Palbociclib for Residual High-Risk Invasive HR-Positive and HER2-Negative Early Breast Cancer—The Penelope-B Trial

RCT found addition of palbociclib to endocrine therapy for one year did not improve invasive disease-free survival 1,250 in women with residual invasive disease after neoadjuvant chemotherapy (median follow-up 42.8 months; HR 0.93; 95% CI, 0.74 to 1.17; P = 0.525).

Journal of Clinical Oncology